He came up with the idea of putting a very small amount of a derivative of ketamine into a nasal spray device. Husseini Manji: It's like an inhaler except it's delivered to the nose. Basically ...

The nasal spray has been administered to more than ... In 2023, the FDA warned of potential risks associated with ketamine treatments. “Known safety concerns associated with the use of ketamine ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

The trailer for the 27th series of South Park has dropped and it appears to include a few swipes at Elon Musk, in regards to ...

In 2019, the Food and Drug Administration approved esketamine (Spravato), a nasal spray for treatment-resistant depression. Research indicates that ketamine therapy helps individuals who did not ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

When Therapy Alone Isn't Enough, Options Like TMS and SPRAVATO® Provide Additional Relief OAK BROOK, Ill., April 8, 2025 ...

The trailer for Season 27 of South Park has been released, and the animated satirical sitcom appears to have a new target: Elon Musk. Newsweek has reached out to X outside of normal working hours via ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one roof would be ideal.

Tasman Therapeutics, Inc. (Tasman) has announced plans to raise $175 million in Series A funding to support the late-stage clinical development and eventual commercialization of R-107. This innovative ...